Myasthenia gravis (MG)

What changes during this transition

Myasthenia gravis is one of the conditions where the gap between community peptide marketing and clinical reality is widest, and where the consequences of a wrong choice are most serious. The Juno position on MG-specific peptide use is straightforward: no peptide currently has a defensible role in MG management. The standard of care is built on decades of antibody-biology research, validated by major trials with named cohorts (MGTX 2016 NEJM for thymectomy, REGAIN for eculizumab leading to FDA approval October 2017, ADAPT for efgartigimod leading to FDA approval December 2021, MycarinG for rozanolixizumab leading to FDA approval June 2023, RAISE for zilucoplan leading to FDA approval October 2023, BeatMG for rituximab in MuSK-positive disease), and endorsed by the AAN 2020 guidance and the International Consensus Guidance 2021 update from the international MG/CMS working group. None of those reference documents list any peptide as a recommended or adjunctive therapy. The peptide substrates catalogued here — BPC-157, TB-500, thymosin alpha-1, LL-37, and NMN — are present in this hub specifically because users encounter them in MG-adjacent community spaces and deserve a clear-eyed answer. Each entry walks through why the substrate does not fit. BPC-157 and TB-500 are sold on tissue-repair narratives that do not address an antibody-mediated junctionopathy. Thymosin alpha-1 carries the sharpest mechanistic concern in the batch — it is registered in multiple jurisdictions for chronic hepatitis B on a T-cell-activating mechanism that runs in the opposite direction from what MG management requires, and it is named for and derived from the thymus in a disease where thymic immune activity is itself part of the pathology (with thymectomy being standard-of-care for non-thymomatous AChR-positive generalized MG per MGTX 2016 NEJM). LL-37 carries directional concern from the broader autoimmune literature, where it has been documented as an autoantigen and innate-immune amplifier in psoriasis, SLE, and rheumatoid arthritis contexts — exactly the wrong signal to import into a disease driven by adaptive autoantibody pathology. NMN is the general-aging supplement spillover entry; it has no MG-pathway link and the fatigue framing it leans on confuses systemic fatigue with the receptor-availability fatigability that defines MG. This is the twenty-eighth deliberate non-elevation in the substrate program. The hub exists, the substrate exists, and the /ask surface will answer honestly when users probe — but the peptide_slugs array is deliberately empty because surfacing any of these five as a discovery card would contradict the substrate framing. MG is not a condition where users should be encouraged to discover peptide options. It is a condition where users should be encouraged to engage deeply with their neuromuscular neurology team, the MG-specific clinical trial landscape (nipocalimab and inebilizumab from the MINT trial readout 2024 are recent additions to a pipeline that has been transformative since 2017), and the patient organization landscape including the Myasthenia Gravis Foundation of America (MGFA, with the load-bearing clinical classification system that has organized the field for decades) and Conquer Myasthenia Gravis. The disease deserves editorial seriousness. Myasthenic crisis is a respiratory-failure medical emergency, and the same MG patient who reads peptide forums today may face an anesthesia decision, an infection requiring antibiotic selection, an imaging study requiring contrast, or an unrelated procedure where the AAN 2020 patient-safety drug-avoidance list becomes immediately load-bearing. The right relationship for an MG patient to have with peptides is not 'which one should I try' but 'why my neuromuscular team's regimen and the drug-avoidance list are the two documents I keep close.' That is the relationship this hub is designed to reinforce.